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A B S T R A C T
Background: Timely implementation of recommended interventions
can provide health beneﬁts to patients and cost savings to the health
service provider. Effective approaches to increase the implementation
of guidance are needed. Since investment in activities that improve
implementation competes for funding against other health generating
interventions, it should be assessed in term of its costs and beneﬁts.
Objective: In 2010, the National Institute for Health and Care Excel-
lence released a clinical guideline recommending natriuretic peptide
(NP) testing in patients with suspected heart failure. However, its
implementation in practice was variable across the National Health
Service in England. This study demonstrates the use of multi-period
analysis together with diffusion curves to estimate the value of
investing in implementation activities to increase uptake of NP test-
ing. Methods: Diffusion curves were estimated based on historic data
to produce predictions of future utilization. The value of an imple-
mentation activity (given its expected costs and effectiveness) was
estimated. Both a static population and a multi-period analysis were
undertaken. Results: The value of implementation interventions
encouraging the utilization of NP testing is shown to decrease over
time as natural diffusion occurs. Sensitivity analyses indicated that
the value of the implementation activity depends on its efﬁcacy and
on the population size. Conclusions: Value of implementation can
help inform policy decisions of how to invest in implementation
activities even in situations in which data are sparse. Multi-period
analysis is essential to accurately quantify the time proﬁle of the value
of implementation given the natural diffusion of the intervention and
the incidence of the disease.
Keywords: cost-effectiveness, heart failure, implementation,
natriuretic peptide (NP) testing.
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Outcomes Research (ISPOR). Published by Elsevier Inc. This is an open
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Introduction
International Adoption of Health Technologies
Problems with slow adoption of health technologies exist inter-
nationally. A study which examined the differential international
diffusion of six health innovations found that rates of adoption
varied signiﬁcantly between innovations and countries [1]. The
international OECD project found that there is widespread varia-
tion in the uptake and diffusion of healthcare technology
amongst OECD countries, indicating that there are opportunities
for more effective integration of such technologies into the health
system. The report comments encouraging the uptake of the
most efﬁcient and effective healthcare technologies remains a
signiﬁcant policy challenge in many OECD countries [2].
Implementation of National Institute for Health and Care
Excellence Clinical Guidelines
In England, the National Institute for Health and Care Excellence
(NICE) produces clinical guidelines and technology appraisals for
the UK National Health Service (NHS). Recommendations are
made based on effectiveness and cost-effectiveness. Interven-
tions (both treatments and diagnostics) which are recommended
by NICE should be available to patients in England and Wales on
the NHS. Indeed the NHS has an obligation to implement NICE
technology assessments within three months of publication [3].
However, uptake of new guidance can be suboptimal [4–9]. For
example, heat maps for the use of medical technologies and
primary care medicines show that there is wide variation
between the medicines patients can access in one part of England
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compared with other parts [4]. It also shows that implementation
rates may vary between disease types; for example, cancer
patients may be well informed and request new treatments.
Cost-effective technologies can only beneﬁt patients and the
health care service if they are used in practice.
Timely implementation of recommended interventions has
the potential for beneﬁts in terms of gains in Quality-Adjusted
Life-Years (QALYs) to patients and/or cost savings to the NHS. It
is possible to ensure that technologies are used in practice by
investing in implementation activities. Early work aimed at
improving implementation was primarily focused at medical
staff [10]. However, this has been supplemented by a wider range
of policy initiatives aimed at promoting the uptake of health
technologies [11]. These include: mandatory inclusion in the
hospital formularies; ﬁnancial incentives to providers (such as
the Quality and Outcomes Framework (QOF) and Commissioning
for Quality and Innovation (CQUIN) scheme); regulatory measures
(such as the NICE compliance regime, benchmarking and leading
by example); initiatives by local NHS organizations; and the
NICE implementation program [11]. Further investment in initia-
tives designed to promote implementation may lead to
beneﬁts to patients and the NHS. The key question is: How and
how much should be invested in implementation initiatives
given that those funds could also be used for other health-
generating activities?
Methods to Evaluate Implementation Initiatives
There are methods to evaluate whether it may be worth investing
in initiatives to speed up implementation. Mason and colleagues
developed a simple deterministic framework to show how the
cost-effectiveness of behavior change was a function of popula-
tion size, together with the cost-effectiveness of the health
technology and the cost-effectiveness of the behavior change
intervention [12]. More recently, Fenwick et al. developed a
uniﬁed framework that brought together value of information
methods with the issue of implementation. This framework
allowed a probabilistic evaluation of investments in implemen-
tation initiatives as expressed through the concepts of expected
value of perfect and speciﬁc implementation [13]. This framework
was extended further by Hoomans et al and Willan and
Eckermann and then applied to an NHS policy initiative by
Walker et al. [14-16].
Walker et al. developed further the previous work on
value of implementation to include patient subgroups, multiple
patient cohorts over time, and the impact of natural diffusion
[17]. Walker et al. deﬁned three concepts, based on those
proposed by Fenwick et al., which are described here. The expected
value of perfect implementation represents the maximum that can
be gained from achieving full implementation and as such
represents a maximum the NHS would be willing to pay. The
expected value of actual implementation represents the maximum
the NHS can invest in implementation activities for speciﬁc
increases in utilization (i.e., for a speciﬁed % increase). All
things equal, the expected value of actual implementation is
larger for interventions with more favorable cost-effectiveness
estimates or with larger patient populations. The value of the
implementation activity is the difference between the expected
value of actual implementation and the cost of the implementa-
tion activity. The value of the implementation activity is larger
the smaller the costs and the larger the increase in utilization
(effectiveness).
This article reports on the application of the value of the
implementation framework to the case study of natriuretic
peptide (NP) testing for the diagnosis of chronic heart failure
(HF) [18]. NP testing was deemed to be cost-effective but has
variable uptake; hence, we were interested in knowing the value
of investing in implementation activities to increase the uptake
of NP testing. We note that the uptake of NP testing is changing
over time in the absence of implementation activities (natural
diffusion). Also, we wanted to estimate the investment for both
the current prevalent population and future cohorts presenting
(given the future natural diffusion). This case study demonstrates
how to estimate the value of implementation for multiple patient
cohorts over time.
Methods
First, the data and assumptions used for the NP testing case
study are described in the next ﬁve subsections and subsequently
single-period and multi-period analyses undertaken are
described in the last subsection.
NP Testing for Suspected HF
B-type natriuretic peptides (B-type natriuretic peptide [BNP] or N-
terminal pro–B-type natriuretic peptide [NTproBNP]), referred to
as NPs, are markers of HF. In 2010, NICE released clinical guide-
line 108 (CG108) on the diagnosis and management of HF. One of
the recommendations in CG108 is testing for NPs in patients with
suspected HF without previous myocardial infarction (MI) in
order to accelerate diagnosis and avoid unnecessary echocardiog-
raphy [18].
The standard of care for trusts that are not yet utilising NP
testing is not dependent on MI history. Typically either a NP test,
electrocardiogram (ECG), or both are used to rule out HF for all
patients independent of MI history. CG108 recommended that
patients with previous MI be referred to specialist assessment
and ECG within 2 weeks. CG108 recommends NP testing for
patients without previous MI:
 If NP testing shows high levels (BNP4 400 pg/ml or NTproBNP
4 2000 pg/ml), the patient is referred directly to specialist
assessment and ECG within 2 weeks.
 If NP testing shows raised levels (BNP 100–400 pg/ml or
NTproBNP 400–2000 pg/ml), the patient is referred to specialist
assessment and ECG within 6 weeks.
 If NP testing shows normal levels (BNP o 100 pg/ml or
NTproBNP o 400pg/ml), HF is unlikely and the patient is not
referred further.
Cost and Effectiveness Data for NP Testing
The value of NP testing corresponds to the lifetime net beneﬁt
from using NP testing for the diagnosis of HF, as described in
NICE CG108, for the average patient presenting with suspected
HF. The economics of the diagnostic section of NICE CG108 was
informed by the health technology assessment (HTA) report by
Mant et al. [19]. However, the cost-effectiveness analysis did not
match the decision problem faced by commissioners in two
important ways: 1) use of diagnostic pathways was determined
by MICE (Male, Infarction, Crepitations, Edema) score rather than
by the history of MI as indicated in CG108 and in clinical practice
and 2) in the comparison, current care is “do nothing” rather than
ECG [20]. Consequently, the model and results from the Mant
et al. HTA needed to be adapted to more closely represent the
CG108. Whilst the lack of ECG as a comparator could not be
resolved within this project, data obtained from the Mant et al.
HTA on MICE score frequencies allowed cost-effectiveness by MI
history to be estimated. The incremental values for CG108 versus
“do nothing” for 1000 persons with suspected HF were calculated
based on data from Mant et al. and are £3881 and þ76.4 QALYs
(See appendix for full details of calculations).
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Population with Suspected HF
The population eligible for NP testing consists of persons
presenting with suspected HF, and the scope of this study
was to produce predictions for England and Wales. The size of
the annual patient population eligible for NP testing in England
and Wales varied by data source. Data from the General
Practice Research Database suggests 22,542, Hospital Episode
Statistics suggests 23,000 to 40,000, an HF study reported
59,000, Shefﬁeld heart failure clinic data suggest 55,000, and a
clinical expert contacted for this study estimated 70,000
[21–23]. Some of these estimates are suspected to be under-
estimates, such as how the Shefﬁeld HF diagnostic clinic data
did not include patients who were admitted to hospital with
acute HF. Hence, the population was assumed to be 70,000 in
the base-case, with 50,000 used in a scenario analysis. Based on
the Cowie et al. [22] study, the prevalence of HF in persons
presenting with suspected HF is 33%. Hence, the population of
persons presenting with suspected HF is estimated to be
210,000 for the base-case analysis (3.7 per 1000 population)
and 150,000 in the scenario analysis.
Utilization and Diffusion Rates
Data on the current utilization of NP testing were obtained from
the NHS atlas of variation in diagnostic services [24]. The average
rate of NP testing was 4.4 per 1000 practice population (minimum
¼ 0; maximum ¼ 14.4; 95% percentiles 0.1–11.4).
Optimal utilization is the average rate of NP testing if the
guidance was fully implemented. This would require data on the
number of persons presenting with symptoms of HF but who did
not have a previous MI. Because no information was found on the
optimal utilization rate, it was assumed to correspond to the NP
testing rate in the 10% and 20% commissioning areas using NP
most frequently, at 8.6 tests for the base-case and 7.1 tests per
1000 people (scenario), respectively. The maximum NP testing
rate of 14.4 tests per 1000 people was not used because only one
commissioning group achieved this rate. This gave a current
optimal utilization of 51% for base-case (63% for scenario analy-
sis). Furthermore, there may be some excess NP testing under-
taken outside CG108, such as using NP as a screening test in the
absence of symptoms [25]. Hence, optimal utilization will be
lower than the observed maximum rate.
A review was undertaken prior to this project which found
that diffusion of healthcare technologies were heterogeneous
[11]. Future utilization rates were predicted from an S-shaped
curve (of the form f(t) ¼ 1/(1 – exp(–at þ k))), ﬁtted to two data
points for 2010 and 2012. This shape of curve was chosen because
it reﬂects the diffusion curve predicted by theory and in numer-
ous observational studies [26]. Utilization in 2012 was based on
estimates from the Diagnostics Atlas data as described previ-
ously. In the NICE costing template (released August 2010), expert
clinical opinion estimated that without the NICE CG108 approx-
imately 30% of patients currently receive NP testing (a BNP or
NTproBNP test) and approximately 90% currently receive an ECG
[27]. These estimates reﬂect the situation in 2010. In the base case
we assume that for these 30%, utilization was 50% of optimal
maximum utilization, that is, 15%. The diffusion curves gener-
ated using these data are presented in Figure 1.
Initiatives to Increase Implementation of NP Testing
From 2011 to 2013, an NP testing implementation initiative led by
healthcare scientists took place in NHS London. In the ﬁrst stage
of the initiative, the barriers to implementation were determined
and a pipeline adoption scale was developed. In 2012, an audit of
25 London provider trusts was undertaken to establish their use
of NP testing (using the NTproBNP test). The audit showed that
trusts’ use of NP testing ranged from “no NP testing” to 13,000 to
14,000 tests annually. The trusts delivering the lowest numbers
or no tests, “intervention trusts,” were supported a variety of
ways including: peer support from London Scientiﬁc & Diagnostic
Network, help with leadership, and commissioning problems. A
2-hour workshop was attended by ﬁve exemplar trusts and three
intervention trusts in February 2013 and knowledge, business
plans, and contact details were shared [28,29]. Data on quantity of
NP testing following the initiative were available for only 2 of the
20 trusts that responded to the initial audit; therefore, a robust
estimate of the effectiveness of the initiative could not be
calculated.
An estimate of the cost of the workshop was developed
using estimates of staff time and consumables based on
information provided by the workshop organizer [28]. Full
details are reported elsewhere [30]. Unit costs for staff time
were taken from the literature [31]. The total cost was estimated
to be £4172 for the 25 trusts in London (£28,187 for the whole of
England and Wales).
A systematic review was conducted to establish the effective-
ness of implementation activities [11]. For the NP case study, it is
suggested that “organizational, educational, opinion leader, edu-
cational outreach, facilitation” are the most relevant initiative
types. Estimates of effect size from the O’Brien et al. study were
used because these were considered the most relevant [32].
In line with those estimates, the base-case analysis an effect
size of 5% was used and a scenario analysis applied an effect
size of 9%.
Analysis
The following quantities were estimated for the NP case study:
expected value of perfect implementation, expected value of actual
implementation, and value of the implementation activity. The for-
mulae used in these analyses are shown in Figure 2.
A multi-period analysis that calculates how value of imple-
mentation varies over time was undertaken. The multiperiod
analysis was started in 2012 because this was the time point for
which utilization data were available and run for 10 years. Future
costs and QALYs accrued were discounted at a rate of 3.5% in line
with the NICE methods guide. The population presenting with
suspected HF was assumed to increase at a rate of 4.2% per
annum. This was based on national Hospital Episode Statistics
data on the number of ﬁnished consultant episodes with a
primary diagnosis of HF, with increases of 3.6% from
2010-2011 to 2011-2012 and 4.8% from 2011-2012 to 2012-2013
and assuming that an increase in NP testing does not reduce the
Fig. 1 – Predicted diffusion of utilization without an
implementation intervention.
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population size [33]. The total value of the implementation
activity over the 10-year period was calculated by summing the
values from the 10 years.
Results
Base Case Analysis
The results of the base case analysis that considers a single
cohort are presented in Table 1. The net monetary beneﬁt (NMB)
of NP testing in patients without previous MI was estimated at
£1,524 for a threshold of £20,000 per QALY gained and £2,288 for a
threshold of £30,000 per QALY gained. The current value to the
NHS, given the patient population currently receiving testing, is
approximately £164 million or 8,230 QALYs for a threshold of
£20,000 per QALY gained.
The expected value of perfect implementation represents the
value of NP testing in the eligible population currently not receiving
testing. The expected value of perfect implementation is approx-
imately £155 million or 7,774 QALYs for the suspected HF population
in England and Wales for a threshold of £20,000 per QALY gained.
The expected value of actual implementation is based on an
implementation activity that is assumed to increase utilization
by 5% (from 51% to 56%). The expected value of actual imple-
mentation is much smaller than the expected value of perfect
implementation. For the overall population in England and
Wales, the NHS could invest up to £16 million for an activity that
increases utilization by 5% at a threshold of £20,000 (approx-
imately £3 million for a 1% increase in utilization).
The value of an implementation activity costing an average of
£4,172 per 25 providers (£28,187 for the whole of England
and Wales) was calculated. Because the implementation activity
has a relatively low cost, the value of the implementa-
tion activity is similar to the expected value of actual implementa-
tion, providing additional value to the NHS of £16 million or 799
QALYs for England and Wales at a threshold of £20,000 per QALY.
Multi-period Analysis
The multi-period analysis demonstrates how the value of imple-
mentation activity accrues over a 10-year period. The results are
presented in Figure 3, which demonstrates that after 5 years the
utilization rates with and without the implementation intervention
are very similar (both close to 100%). Therefore, the value of
implementation is very small in the second half of the 10-year
period. The total value of implementation activity over 10 years is
£76 milllion.
Scenario Analyses
Three scenario analyses were undertaken to explore the impact
of key uncertainties on model results: 1) Population size: annual
Fig. 2 – Components involved in value of implementation analysis together with formulae.
Table 1 – Static population analysis with base-case assumptions.
Static population analysis WTP ¼ £20,000 WTP ¼ £30,000
NMB NHB NMB NHB
Net beneﬁt to the NHS (per patient) £1,518 0.076 £2,282 0.076
Current value of technology given current utilization and population size for England
and Wales. Population ¼ 210000, current utilization ¼ 4.43 (51%)
£163,969,752 8198 £246,476,558 8216
Expected value of perfect implementation. Value of increasing utilization from current
to desirable maximum. Current utilization ¼ 4.43, desirable maximum ¼ 8.62 (100%)
£154,895,869 7745 £232,836,850 7761
Expected value of actual implementation. Value of increasing utilization from current
to achievable. Current utilization ¼ 4.43, achievable utilization with intervention ¼
4.86 (56%)
£15,943,281 797 £23,965,670 799
Value of the implementation activity. Expected value of actual implementation minus
cost of intervention (£28,187)
£15,915,094 796 £23,937,484 798
NHB, net health beneﬁt; NHS, National Health Service; NMB, net monetary beneﬁt; WTP, willingness to pay.
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rate of suspected HF: 0.27% (population of 150,000); 2) Current
utilization of BNP testing: 63%; and 3) Efﬁcacy of the implemen-
tation intervention: 9% increase. The results indicated that
population size and efﬁcacy of the implementation intervention
both had a signiﬁcant impact on the value of the implementation
activity (reduction and increase to £11 million and £28 million,
respectively) (see Table 2). Additional sensitivity analyses which
explore the impact of varying parameter values further are
provided in the appendix.
Discussion
Summary of Results
This study demonstrates the application of a framework for
calculating the value of implementation activity to a case study:
NP testing in diagnosing chronic HF. A multi-period analysis uses
diffusion curves to predict change in utilization over time and
estimating the value of implementation over a 10-year time
period. The analysis demonstrates that the value of investing in
implementation may decrease over time as utilization increases.
Based on this analysis, the NP testing implementation activity
modeled here is predicted to provide additional value to the NHS
of £16 million for England and Wales (at a threshold of £20,000
per QALY).
The framework can be applied to any existing cost-
effectiveness analysis, thus helping a decision maker to quantify
the value of investing resources in increasing utilization in a
manner consistent with the value assessment of new interven-
tions conducted by NICE.
Evidence to Populate a Value of Implementation Model
This case study provides a useful demonstration of the practical
challenges faced in populating such a model. The main limita-
tions of the analysis were a lack of evidence on cost-effective-
ness, effectiveness of implementation interventions, utilization,
diffusion of utilization, and population size. In these areas in
which key uncertainties exist in data used to inform the model,
undertaking scenario analyses is essential. This case study
suggests that the availability of evidence to inform a model using
this framework could be an issue in many situations.
Estimates of utilization were made, but these required
assumptions regarding the maximum optimal utilization rate. A
better understanding of the utilization and diffusion of health
technologies is required for accurate modeling, and consideration
should be given to routinely collecting this after reimbursement
decisions. Without this information, it is not possible to assess
what effect the reimbursement process has actually had, nor the
value of investing in implementation initiatives.
There was considerable uncertainty surrounding the evidence
on population size. Accurate estimates of population size are also
essential to estimate utilization rates. The differences in estimates
of population size from different published data sources highlights
the importance of validating data sources with clinical experts.
In addition, there were no estimates of what the optimal
utilization should be for the indicated population. In other areas
of medicine, information on optimal utilization will be clearer
because licensing of pharmaceuticals ensures clearer deﬁnitions
of patient populations. However, license-based estimates are less
useful if there are competitor products because the maximum
will be dependent on market share.
The comparator in the economic analysis was “do nothing”
rather than ECG, so the cost-effectiveness is likely to be over-
estimated; hence, results will overestimate the value of imple-
mentation activities. The importance of publishing incremental
costs and QALYs related to clinical guidelines compared with
current care is thus highlighted. Data on the effectiveness of the
London implementation initiative were not available. Robust data
on the cost and effectiveness of implementation interventions
should be collected where possible to allow for evaluation.
Comparison with Previous Studies
One of the ﬁrst systematic reviews of implementation initiatives
by Grimshaw et al. identiﬁed 11 cost-effectiveness analyses [10].
The studies were purely observational, with no attempt at
modeling the longer-term effects on diffusion and patient out-
comes. Furthermore, neither QALYs nor probabilistic sensitivity
analyses were used in any of the studies. A more recent review
found a similar situation, with poor methods and reporting [34].
Mason et al. present a method for calculating policy cost-
effectiveness and illustrate it with examples from a trial of
educational outreach by community pharmacists to inﬂuence
physician prescribing in England [12]. The intervention to
Fig. 3 – Value of implementation: Multiperiod analysis. HF,
heart failure; WTP, willingness to pay.
Table 2 – Value of implementation: Scenario
analyses.
Scenario Net monetary beneﬁt
(willingness-to-pay
threshold: £20,000 per
QALY)
Base case: Annual rate of
suspected HF: 0.37%; Current
utilization: 51%; Efﬁcacy of
implementation intervention:
5%
£16.0 million
Population size: Annual rate of
suspected HF 0.27%
(population of 150,000)
£11.4 million
Current utilization of BNP
testing: 63%
£16.0 million
Efﬁcacy of the implementation
intervention: 9% increase
£28.1 million
BNP, B-type natriuretic peptide; HF, heart failure; QALY, quality-
adjusted life-year.
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increase implementation was found to be cost-effective; how-
ever, this is based on a one-off increase in uptake, which fails to
recognize the dynamics of diffusion and patient incidence.
In the United Kingdom, the QOF policy initiative to change the
clinical behavior of general practitioners has been examined in
considerable detail, including ﬁve economic evaluations [35]. Of
the ﬁve studies cited, only Walker and colleagues produces ICER
[16]. Due to lack of availability of data on baseline performance,
the actual cost-effectiveness could not be determined by Walker
et al., and as a result, the authors analyzed the potential cost-
effectiveness. Despite using a probabilistic framework, the anal-
yses did not examine the value of implementation.
Hoomans et al. examined the value of information and the value
of implementation for treatments for metastatic hormone-
refractory prostate cancer. The use of a probabilistic framework
made it possible to examine whether it was worthwhile investing in
implementation strategies and the maximum amount of invest-
ment that would be cost-effective. This was then extended in
another case study, this time using empirical estimates of the
effectiveness of alternative implementation strategies and examin-
ing variations between different service providers [36,37].
The other case study within our program of work was used to
explore the impact of patient subgroups in a more detailed way.
This study of novel oral anticoagulants (NOACs) for the preven-
tion of stroke and systemic embolism in patients with atrial
ﬁbrillation found that there is value in additional implementation
activities, particularly in targeting patients with average or poor
warfarin control. Additional investment in an educational activ-
ity that increases utilization by 5% in the entire population
currently on warfarin generates additional 254 QALYs versus
973 QALYs in the subgroup with average to poor warfarin control
[38].
This study adds to the results of previous research by high-
lighting the limitations of available data and exploring the impact
of these uncertainties via sensitivity analyses. We conclude that
data limitations have a considerable impact on estimates of value
of implementation. No previous studies have undertaken a
dynamic multi-period analysis and as such underestimate the
value generated by the treatment of future cohorts and ignore the
importance of diffusion dynamics. Our study demonstrates how
it is possible to estimate diffusion curves on the basis of historic
data to produce predictions of future utilization and how these
can be incorporated into a multi-period analysis.
Further Work
A probabilistic approach to representing parameter uncertainty
(in which parameters are sampled from distributions) could be
utilized within this framework. Incorporation of this would allow
analyses examining the value in reducing uncertainties related to
the model parameters. As such, in situations in which the value
of implementation of the implementation activity is low, assess-
ments could be made as to research priorities aimed at reducing
key uncertainties.
Further research on diffusion curves for health technologies is
recommended because this is a key modeling component for
estimating the value of implementation. Furthermore, it is
known that the level of implementation can change the prices
of some medical technologies. For example, evidence shows that
price can be negatively related to the uptake for some technol-
ogies, with lower prices being generated through reductions in
production costs and increased supplier competition [39]. Includ-
ing such a relationship within analyses is potentially important;
however, the empirical evidence on this relationship is sparse for
health technologies.
A further relationship to consider is whether there may be a
higher cost of implementation for a subgroup consisting of the
slowest adopters. Lastly, consideration should be given as to
whether the nature of the patient population changes with
implementation. For example, Hoyle and Anderson investigate
the impact of a technology being applied to changing patient
populations [40]. Research funding bodies or reimbursement
agencies should consider making key information required by
this framework compulsory in submissions made by manufac-
turers. For example, past and current utilization (to allow a
diffusion curve to be constructed), current and future population
size, and the maximum implementation level. Likewise, reim-
bursement bodies should build in data collection to the post-
decision period so that the level of implementation can be
measured and the value of initiatives assessed.
Conclusions
The framework on the value of implementation can help health
services such as the NHS quantify the value of investing resources
in increasing utilization in a manner consistent with the value
assessment of new interventions. The expected value of actual
implementation is the maximum investment that the NHS should
consider for a given increase in utilization. Implementation activ-
ities should be considered for investment by the NHS as long as
their cost is not greater than their value of actual implementation
(value of implementation Z 0). Data problems exist for analyses of
this kind; however, they present the correct framework for making
efﬁcient investment decisions. Collecting the necessary data as part
of the reimbursement process is essential if we are to assess what
effect the reimbursement process has actually had and the value of
investing in implementation initiatives.
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